Indications for: AMICAR ORAL SOLUTION
Bleeding associated with fibrinolysis.
Initially 5g during 1st hour, then 1g/hour for 8 hours or until bleeding is controlled.
AMICAR ORAL SOLUTION Contraindications:
Active intravascular clotting process. Disseminated intravascular coagulation without concomitant heparin.
AMICAR ORAL SOLUTION Warnings/Precautions:
Upper urinary tract bleeding: not recommended. Cardiac, hepatic or renal disease. Risk of myopathy with long-term use; monitor creatine phosphokinase (CPK); discontinue if CPK rises. Avoid rapid IV administration. Neonates. Pregnancy (Cat.C). Nursing mothers.
AMICAR ORAL SOLUTION Classification:
AMICAR ORAL SOLUTION Interactions:
Avoid concomitant Factor IX complex or Anti-inhibitor Coagulant concentrates; may increase thrombosis risk.
Bradycardia, hypotension, GI upset, edema, headache, malaise, CNS effects, thrombosis, others; rare: myopathy.
Renal excretion is the primary route of elimination. Terminal elimination half-life is approximately 2 hours.
Generic Drug Availability:
Tabs—30; Oral soln—236.5mL